Assessment Vitamin D Analogues Intake Pathways on the Proteins Which Involved in Metabolic Rate in Obese Subjects

Tehran University of Medical Sciences

Status: Unknown

Conditions: Obesity

Treatments: Dietary Supplement: Placebo; Dietary Supplement: Vitamin D analogue

Study type: Interventional

Funder types: Other

Identifiers

NCT01894295

91-03-27-18831

Details and patient eligibility

About

The aim of this double blind clinical trial study is to investigate whether alphacalcidol treatment in obese subjects can affect the resting metabolic rate. Moreover, the investigators will evaluate the pathways of Nesfatin-1, Peroxisome proliferator-activated receptor gamma (PPARγ) and eroxisome proliferator-activated receptor- coactivator-1 α (PGC1α) protein which may lead to change in metabic rate following treatment with either alphacalcidol or placebo.

Enrollment: 96 estimated patients

Sex: All

Ages: 22 to 52 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Age 22-52 years Body mass index equal or more than 30

Exclusion criteria

Acute or chronic inflammatory disease History of hypertension Alcohol or drug abuse History of any condition affecting inflammatory markers Thyroid diseases Malignancies Current smoking Diabetes mellitus Sustained hypertension Heart failure Acute or chronic infections Hepatic or renal diseases Use of PPARγ agonist drug

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

96 participants in 2 patient groups, including a placebo group

Vitamin D analogue

Experimental group

Description:

1-α hydroxyvitamin D3; dose 0.25, 0.5 and 1 microgram.

Treatment:

Dietary Supplement: Vitamin D analogue

Placebo

Placebo Comparator group

Description:

Corn oil pearl Capsules 1 gram

Treatment:

Dietary Supplement: Placebo